Chemotherapy-induced Nausea and Vomiting Drugs

Chemotherapy-induced Nausea and Vomiting Drugs

Global Chemotherapy-induced Nausea and Vomiting Drugs Market to Reach US$5.1 Billion by 2030

The global market for Chemotherapy-induced Nausea and Vomiting Drugs estimated at US$3.6 Billion in the year 2023, is expected to reach US$5.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Neurokinin NK1 Receptor Antagonist segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$983.5 Million While China is Forecast to Grow at 4.9% CAGR

The Chemotherapy-induced Nausea and Vomiting Drugs market in the U.S. is estimated at US$983.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$809.8 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.8% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Chemotherapy-induced Nausea and Vomiting Drugs Market - Key Trends and Drivers Summarized

Why Is Chemotherapy-Induced Nausea and Vomiting (CINV) a Major Concern?

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most troubling and distressing side effects of cancer treatment, significantly affecting the quality of life for millions of cancer patients worldwide. But what makes CINV such a persistent concern in modern oncology despite advances in treatment methods? Chemotherapy, while effective at targeting and killing rapidly dividing cancer cells, also impacts healthy cells, particularly those lining the gastrointestinal tract. This triggers a cascade of signals to the brain that result in nausea and vomiting. For many patients, the fear and experience of CINV can be as debilitating as the cancer itself, causing anxiety, loss of appetite, dehydration, and in severe cases, malnutrition. A significant proportion of patients undergoing chemotherapy experience CINV to some degree, even with the use of modern antiemetics. This can lead to delays in chemotherapy treatments or dose reductions, compromising the overall efficacy of cancer therapy. Moreover, uncontrolled CINV can result in extended hospital stays, increased healthcare costs, and diminished patient morale. Given these significant impacts, managing CINV effectively has become a crucial aspect of oncology care, emphasizing the need for reliable and advanced antiemetic therapies to improve patient outcomes.

How Do CINV Drugs Work to Control Symptoms?

Chemotherapy-induced nausea and vomiting drugs, known as antiemetics, work by targeting the physiological pathways responsible for triggering nausea and vomiting. But how exactly do these drugs function, and what makes them effective? CINV drugs generally fall into several classes, each targeting a different aspect of the vomiting reflex. One of the primary mechanisms involves the blocking of serotonin, a neurotransmitter released by the body in response to chemotherapy, which binds to 5-HT3 receptors in the gut and brainstem to trigger nausea and vomiting. Drugs like ondansetron, granisetron, and palonosetron, which are 5-HT3 receptor antagonists, effectively prevent this chain reaction, offering significant relief for many patients. Another class of drugs targets neurokinin-1 (NK-1) receptors, which play a role in the delayed phase of CINV that occurs 24 hours or more after chemotherapy. Aprepitant and fosaprepitant are examples of NK-1 receptor antagonists that, when used in combination with serotonin blockers, provide a broader spectrum of relief. Corticosteroids, such as dexamethasone, are often added to these regimens to enhance the effectiveness of the antiemetics. Benzodiazepines like lorazepam may also be used, particularly for patients who experience anticipatory nausea and vomiting due to anxiety related to previous chemotherapy sessions. This multi-faceted approach, combining drugs from different classes, helps prevent both the immediate and delayed phases of CINV, offering patients a greater chance of tolerating their treatment plans without interruption.

What Innovations Are Shaping the Future of CINV Treatment?

Recent advancements in the treatment of CINV are transforming how these side effects are managed, aiming to improve both the efficacy of antiemetic therapies and the overall experience for patients. So, what are the major innovations that are driving these changes? One of the most significant trends is the development of long-acting and extended-release formulations of antiemetic drugs, which aim to reduce the need for multiple doses and improve patient compliance. Palonosetron, for example, is a second-generation 5-HT3 receptor antagonist with a longer half-life than earlier drugs, providing up to five days of protection from CINV with a single dose. This is especially beneficial for patients undergoing highly emetogenic chemotherapy regimens, where continuous control over nausea and vomiting is necessary. Another innovation is the exploration of new drug delivery systems, such as transdermal patches and sublingual tablets, which make it easier for patients to take their medications without relying on oral administration—an important consideration for those already experiencing nausea. Additionally, research into the genetic underpinnings of CINV is gaining momentum, with scientists investigating biomarkers that can predict a patient’s likelihood of experiencing severe nausea and vomiting. This opens the door to personalized treatment strategies, where antiemetic regimens can be tailored based on an individual’s genetic makeup, offering more targeted and effective solutions. Furthermore, new combination therapies are being developed that combine NK-1 antagonists and 5-HT3 receptor antagonists in single-dose formulations, simplifying treatment protocols while maintaining efficacy. These advances reflect a deeper understanding of the mechanisms behind CINV and a growing effort to reduce the burden on patients through more sophisticated and patient-friendly treatment options.

What Is Driving the Growth in the Chemotherapy-Induced Nausea and Vomiting Drugs Market?

The growth in the chemotherapy-induced nausea and vomiting (CINV) drugs market is driven by several factors, including advances in pharmaceutical technologies, the increasing global cancer burden, and evolving patient care priorities. As cancer incidence continues to rise, particularly in regions with aging populations, the demand for effective CINV management has surged, driving pharmaceutical companies to innovate and expand their offerings. One of the major growth drivers is the increasing sophistication of antiemetic drug formulations. Long-acting drugs and combination therapies that improve convenience and adherence have expanded the options for healthcare providers, enabling them to tailor treatments more effectively. The growing trend toward personalized medicine is also propelling the market, as researchers develop more targeted antiemetics based on genetic markers that predict a patient’s susceptibility to CINV. Additionally, the rising adoption of combination chemotherapy regimens, which are more likely to cause severe nausea and vomiting, has intensified the need for highly effective antiemetic solutions, further driving market demand. Another key factor contributing to market growth is the expanding access to oncology treatments in emerging economies, where cancer care infrastructure is improving. This is increasing the demand for supportive care medications like CINV drugs. As healthcare systems around the world place greater emphasis on improving quality of life for cancer patients, there is a growing focus on minimizing the side effects of chemotherapy, including nausea and vomiting. Advances in drug delivery technologies, such as transdermal systems and orally disintegrating tablets, are addressing issues of compliance and convenience, which are critical for patient adherence, particularly in outpatient settings. Growing awareness of the psychological and physical impact of CINV among patients and caregivers is leading to earlier and more proactive management, further driving the adoption of these drugs across the global healthcare landscape.

Select Competitors (Total 23 Featured) -

• Acacia Pharma Group Plc
• Aphios Corporation
• Baxter International Inc.
• Dr. Reddy's Laboratories Ltd.
• Eisai Co., Ltd.
• Especificos Stendhal S.A. DE C.V.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Helsinn Healthcare SA
• Heron Therapeutics, Inc.
• Kyowa Hakko Kirin Co., Ltd.
• Lee's Pharmaceutical Holdings Ltd.
• Merck & Co., Inc.
• Midatech Pharma PLC
• Mundipharma Pte., Ltd.
• Mylan N.V.
• Ono Pharmaceutical Co., Ltd.
• Opko Health, Inc.
• Orchid Chemicals & Pharmaceuticals Ltd
• Otsuka Pharmaceutical Co., Ltd.
• Purdue Pharma LP
• Sandoz International GmbH
• SciClone Pharmaceuticals, Inc.
• Shin Nippon Biomedical Laboratories Ltd. (SNBL)
• Solasia Pharma K.K.
• Specialised Therapeutics Asia Pte Ltd
• Sun Pharmaceutical Industries Ltd.
• Taiho Pharmaceutical Co., Ltd.
• Tesaro, Inc.
• Teva Pharmaceutical Industries Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.